5. Depression and Cardiovascular Disease: The Safety of Antidepressant Drugs and their Ability to Improve Mood and Reduce Medical Morbidity

  1. Alexander Glassman2,3,
  2. Mario Maj4 and
  3. Norman Sartorius5
  1. Alexander H. Glassman2,3 and
  2. J. Thomas Bigger Jr.1

Published Online: 14 NOV 2010

DOI: 10.1002/9780470972304.ch5

Depression and Heart Disease

Depression and Heart Disease

How to Cite

Glassman, A. H. and Bigger, J. T. (2010) Depression and Cardiovascular Disease: The Safety of Antidepressant Drugs and their Ability to Improve Mood and Reduce Medical Morbidity, in Depression and Heart Disease (eds A. Glassman, M. Maj and N. Sartorius), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470972304.ch5

Editor Information

  1. 2

    Department of Clinical Psychopharmacology, New York State Psychiatric Institute, New York, NY, USA

  2. 3

    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY, USA

  3. 4

    Department of Psychiatry, University of Naples SUN, Naples, Italy

  4. 5

    Association for the Improvement of Mental Health Programmes, Geneva, Switzerland

Author Information

  1. 1

    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA

  2. 2

    Department of Clinical Psychopharmacology, New York State Psychiatric Institute, New York, NY, USA

  3. 3

    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY, USA

Publication History

  1. Published Online: 14 NOV 2010
  2. Published Print: 5 NOV 2010

ISBN Information

Print ISBN: 9780470710579

Online ISBN: 9780470972304

SEARCH

Keywords:

  • Depression and Cardiovascular Disease: The Safety of Antidepressant Drugs and their Ability to Improve Mood and Reduce Medical Morbidity;
  • cardiovascular disease (CVD);
  • The Safety of Antidepressant Drugs;
  • The Ability of Antidepressant Drugs to Influence Medical Morbidity and Mortality;
  • Implementing Treatment of Depression in a Medical Setting;
  • selective serotonin reuptake inhibitors (SSRIs);
  • left ventricular ejection fraction (LVEF);
  • Sertraline Antidepressant Heart Attack Randomised Trial (SADHART);
  • National Heart, Lung, and Blood Institute (NHLBI);
  • cognitive behavioural therapy (CBT)

Summary

This chapter contains sections titled:

  • The Safety of Antidepressant Drugs

  • The Ability of Antidepressant Drugs to Influence Medical Morbidity and Mortality

  • Implementing Treatment of Depression in a Medical Setting

  • Conclusions

  • Acknowledgement

  • References